Innocan Pharma Corp. Stock

Price

Target price

WKN: A2PSPW / Name: Innocan Pharma Corp. / Stock / ? /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Your prediction

Innocan Pharma Corp. Stock

Our community identified positive and negative aspects for Innocan Pharma Corp. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Innocan Pharma Corp. stock. On the other hand our users think that "General Risks" could be a problem in the future.

What does Innocan Pharma Corp. do?

Pros and Cons of Innocan Pharma Corp. in the next few years

Pros

G***** c******* t* c**********

C******** o* t** e**********

S********** s********

Cons

M***** P*******

W********* I********* f** t** n*** y****

B****

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2024-08-01

When delving into the financials of Innocan Pharma Corp., a mixed bag emerges. The numbers tell a story of a company striving for growth but grappling with significant operational challenges. A glance at the balance sheets, income statements, and cash flow figures suggests that while there are signs of potential, the current state is far from robust. This analysis will explore the strengths and weaknesses of Innocan's financial landscape, revealing both the opportunities and threats it faces in the competitive biopharmaceutical industry.

Pros of Innocan Pharma's Financials

Cash On Hand: As of the end of 2022, Innocan had $4,947,000 in cash, down significantly from $11,048,000 in 2021. However, this liquidity still provides a crucial buffer for operations, research, and development activities. It suggests that the company has the foundational resources needed to fuel its innovation and address immediate operational costs.

Feedback